中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.01 seconds)

    Stable immunogenic product comprising antigenic heterocomplexes
    1.
    发明授权
    Stable immunogenic product comprising antigenic heterocomplexes 有权
    包含抗原异复合物的稳定的免疫原性产物

    公开(公告)号：US08697047B2

    公开(公告)日：2014-04-15

    申请号：US13149041

    申请日：2011-05-31

    Applicant: Helene Le Buannec ,  Daniel Zagury

    Inventor： Helene Le Buannec ,  Daniel Zagury

    IPC: A61K39/21 ,  C07K1/00 ,  C07K14/00

    CPC classification number: A61K39/385 ,  A61K39/0005 ,  A61K47/6415 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/6075 ,  A61K2039/6081 ,  A61K2039/62 ,  A61K2039/622

    Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

    Abstract translation: 本发明涉及用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物。 本发明的特征在于其包含通过（i）抗原蛋白分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物，并且其中少于40％的抗原蛋白（i）与蛋白质载体连接 分子（ii）通过共价键。

    Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
    3.
    发明申请
    Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus 失效
    包含hpv-16病毒的突变e7蛋白的非免疫抑制致免疫或疫苗组合物

    公开(公告)号：US20060233820A1

    公开(公告)日：2006-10-19

    申请号：US10512045

    申请日：2003-04-04

    Applicant: Daniel Zagury ,  Helene Le Buanec ,  Bernard Bizzini

    Inventor： Daniel Zagury ,  Helene Le Buanec ,  Bernard Bizzini

    IPC: A61K39/12

    CPC classification number: C07K14/005 ,  A61K2039/53 ,  C07K2319/00 ,  C12N2710/20022 ,  C12N2740/16322

    Abstract: The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in: i. the 1-19 amino acid sequence of sequence SEQ ID No. 3; ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and iii. the 30-98 amino acid sequence of sequence SEQ ID No.;

    Abstract translation: 本发明涉及诱导针对HPV-16乳头瘤病毒天然E7蛋白的免疫应答的免疫原性或疫苗组合物，而不同时诱导免疫抑制，所述组合物包含作为活性成分的非免疫抑制性突变E7蛋白，其包含氨基酸序列 包括从N端到C端，在：i。 序列SEQ ID No.3的1-19氨基酸序列; ii。 氨基酸序列具有（a）至少一个氨基酸的取代，与序列SEQ ID No.3的20-29对应氨基酸序列相比，或（b）至少4个连续氨基酸的缺失，与 序列SEQ ID No.3的20-29对应氨基酸序列; 和iii。 序列SEQ ID No的30-98氨基酸序列;

    Stable immunogenic product comprising antigenic heterocomplexes
    6.
    发明授权
    Stable immunogenic product comprising antigenic heterocomplexes 有权
    包含抗原异复合物的稳定的免疫原性产物

    公开(公告)号：US07972603B2

    公开(公告)日：2011-07-05

    申请号：US10527975

    申请日：2003-09-16

    Applicant: Helene Le Buannec ,  Daniel Zagury

    Inventor： Helene Le Buannec ,  Daniel Zagury

    IPC: A61K39/21 ,  C07K1/00 ,  C07K14/00

    CPC classification number: A61K39/385 ,  A61K39/0005 ,  A61K47/6415 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/6075 ,  A61K2039/6081 ,  A61K2039/62 ,  A61K2039/622

    Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

    Abstract translation: 本发明涉及用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物。 本发明的特征在于其包含通过（i）抗原蛋白分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物，并且其中少于40％的抗原蛋白（i）与蛋白质载体连接 分子（ii）通过共价键。

    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's
    7.
    发明授权
    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 有权
    使用无活性免疫抑制和/或血管生成免疫原性蛋白，用于产生分泌型IgA

    公开(公告)号：US07351554B2

    公开(公告)日：2008-04-01

    申请号：US11302286

    申请日：2005-12-14

    Applicant: Daniel Zagury

    Inventor： Daniel Zagury

    IPC: C12P21/06

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.

    Abstract translation: 一种产生分泌型IgA抗体诱导粘膜免疫的方法，其中和阻断源自癌细胞的天然E7蛋白，来自人乳头瘤病毒感染的细胞或免疫系统细胞。 该方法包括向有需要的患者施用含有天然E7蛋白的活性化合物的疫苗组合物，其性质通过物理和/或化学处理通过遗传重组已被灭活至少70％ 或通过辅助条件; 免疫抑制和/或血管生成天然E7蛋白的无活性片段; 编码通过突变至少70％灭活的免疫抑制和/或血管生成天然E7蛋白质的DNA分子; 或编码免疫抑制和/或血管生成天然E7蛋白的无活性片段的DNA分子; 以及粘膜免疫佐剂。

    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's
    9.
    发明申请
    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 有权
    使用无活性免疫抑制和/或血管生成免疫原性蛋白，用于产生分泌型IgA

    公开(公告)号：US20060153863A1

    公开(公告)日：2006-07-13

    申请号：US11302286

    申请日：2005-12-14

    Applicant: Daniel Zagury

    Inventor： Daniel Zagury

    IPC: A61K39/12

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.

    Abstract translation: 一种产生分泌型IgA抗体诱导粘膜免疫的方法，其中和阻断源自癌细胞的天然E7蛋白，来自人乳头瘤病毒感染的细胞或免疫系统细胞。 该方法包括向有需要的患者施用含有天然E7蛋白的活性化合物的疫苗组合物，其性质通过物理和/或化学处理通过遗传重组已被灭活至少70％ 或通过辅助条件; 免疫抑制和/或血管生成天然E7蛋白的无活性片段; 编码通过突变至少70％灭活的免疫抑制和/或血管生成天然E7蛋白质的DNA分子; 或编码免疫抑制和/或血管生成天然E7蛋白的无活性片段的DNA分子; 以及粘膜免疫佐剂。

    Stable immunogenic product comprising antigenic heterocomplexes
    10.
    发明申请
    Stable immunogenic product comprising antigenic heterocomplexes 有权
    包含抗原异复合物的稳定的免疫原性产物

    公开(公告)号：US20060013800A1

    公开(公告)日：2006-01-19

    申请号：US11135660

    申请日：2005-05-24

    Applicant: Helene Le Buanec ,  Daniel Zagury

    Inventor： Helene Le Buanec ,  Daniel Zagury

    IPC: A61K38/19 ,  C07K14/525

    CPC classification number: A61K39/385 ,  A61K39/0005 ,  A61K47/6415 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/6075 ,  A61K2039/6081 ,  A61K2039/62 ,  A61K2039/622

    Abstract: A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

    Abstract translation: 用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物，其特征在于其包含由（i）抗原性蛋白质分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物， 超过40％的抗原蛋白质（i）通过共价键与蛋白质载体分子（ii）连接。

Patent Agency Ranking